BioSpace News Archive

IN8bio, Inc. announced the additions to its clinical and regulatory team as the Company seeks to expand its clinical pipeline with at least one new company sponsored investigational new drug application this year.

Artelo Biosciences, Inc. today announced that ART27.13, a peripherally selective G-Protein Coupled Receptor (GPCR) full agonist currently in clinical development for cancer-related anorexia.

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the presentation of preclinical data and initial pharmacokinetic (PK) and pharmacodynamic (PD) data from the ongoing Phase I clinical study of CCX559 during a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Oncternal Therapeutics, Inc. today announced that it has deprioritized further development of ONCT-216 to reallocate resources to zilovertamab.

Gift of Life Biologics Inc., a vertically integrated supplier of allogeneic cellular starting material to the biopharmaceutical industry, announces the close of its $6m seed financing round.

Apollo Endosurgery, Inc. announced that the Company is scheduled to release financial results for the first quarter ended March 31, 2022 on Tuesday, May 3, 2022, after market close.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced that new preclinical findings of ALLO-316, an AlloCAR T therapy targeting CD70 for the treatment of renal cell carcinoma (RCC), were presented in a poster session of the 2022 American Association for Cancer Research (AACR) Annual Meeting.

TransCode Therapeutics, Inc. is pleased to announce that its Co-Founder and Chief Technology Officer, Dr. Zdravka Medarova, will moderate the 7th Annual RNA Medicine Symposium, co-sponsored by the Harvard Medical School Initiative for RNA Medicine and the Cancer Center at Beth Israel Deaconess Medical Center, on April 28, 2022.

Ascletis Pharma Inc. announces that Ascletis Pharmaceuticals Co., Ltd. has signed an agreement with China Meheco International Co., Ltd. for distribution of its ritonavir tablets in Chinese mainland.

Ceapro Inc. announced operational highlights and financial results for the fourth quarter and full year ended December 31, 2021.